Genentech Inc. didn’t need to wait until Thanksgiving for the U.S. FDA to make up its mind. More than a month ahead of its PDUFA date, the agency approved the firm’s first-line breast cancer treatment ...

Feel free to distribute or cite this material, but please credit OpenSecrets. For permission to reprint for commercial uses, such as textbooks, contact OpenSecrets: [email protected] ...

Amgen (Thousand Oaks, CA, USA) and Genentech (S. San Francisco, CA, USA) together accounted for almost one–third of the sector revenue and one–quarter of the R&D spend. For biotech company ...

Genentech began a pivotal phase 2 trial of GDC ... which they are now characterizing further (Proc. Natl. Acad. Sci. USA 106, 14132–14137, 2009). Each displayed differing tissue specificities ...

As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceutical companies to reflect on how their industry is being portrayed in the presidential ...

Roche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its repertoire. The three drug discovery deals are with Convelo Therapeutics in neurological ...

Feel free to distribute or cite this material, but please credit OpenSecrets. For permission to reprint for commercial uses, such as textbooks, contact OpenSecrets: [email protected] ...

Roche Group unit Genentech said that the Food and Drug Administration approved Itovebi for treating certain breast cancer. The approval is for Itovebi in combination with palbociclib and ...

Aviv Regev, executive vice president and head of Genentech Research & Early Development (gRED) NVIDIA’s push into the life sciences sector has been rewarded by a wide-ranging deal with Roche’s ...

While she tried everything she could to keep her skin healthy—moisturizing regularly and drinking plenty of water—Elisha ...

USA TODAY delivers a curated mix of the day’s most important news and information to pique your curiosity and explore your passions. Episode by episode, we leave you with a better understanding ...

Background Hepatocellular carcinoma (HCC) is plagued by failures across the cancer care continuum, leading to frequent late-stage diagnoses and high mortality. We evaluated the effectiveness of mailed ...